In that regard, it is relevant to mention that pre-clinical studies have demonstrated that blinatumomab treatment could lead to the reinvigoration of T cell anti-tumor responses ex vivo, through T cell activation, proliferation, cytokine expression and, finally, antigen-independent cytotoxicity from both CD4+ and CD8+ T cells [114]. The gene discussed is CD8A; the disease is neoplasm.